Аналитики считают Nautilus Biotechnology более перспективной инвестицией, чем MaxCyte, из-за высокого потенциала роста цен

Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends. Analyst Ratings This is a summary of recent recommendations for Nautilus Biotechnology and MaxCyte, as provided by MarketBeat. Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 311.35%. MaxCyte has a consensus price target of $5.00, indicating a potential upside of 287.60%. Given Nautilus Biotechnology’s higher probable upside, equities analysts clearly believe Nautilus Biotechnology is more favorable than MaxCyte. Risk and Volatility Institutional & Insider Ownership 50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 4.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Profitability This table compares Nautilus Biotechnology and MaxCyte’s net margins, return on equity and return on assets. Valuation and Earnings This table compares Nautilus Biotechnology and MaxCyte”s top-line revenue, earnings per share and valuation. MaxCyte has higher revenue and earnings than Nautilus Biotechnology. MaxCyte is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks. Summary MaxCyte beats Nautilus Biotechnology on 7 of the 11 factors compared between the two stocks. About Nautilus Biotechnology Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. About MaxCyte MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.